debrisoquin has been researched along with amodiaquine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Bertilsson, L; Gustafsson, LL; Mahindi, M; Nordmark, A; PihlsgÄrd, M; Wennerholm, A | 1 |
1 trial(s) available for debrisoquin and amodiaquine
Article | Year |
---|---|
Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo.
Topics: Administration, Oral; Adult; Amodiaquine; Antihypertensive Agents; Antimalarials; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Confidence Intervals; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Debrisoquin; Drug Interactions; Humans; Losartan; Middle Aged; Phenotype; Time Factors | 2006 |
1 other study(ies) available for debrisoquin and amodiaquine
Article | Year |
---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |